title: Flavonoids inhibit angiogenic cytokine production by human glioma cells.
abstract: VEGF and TGF-β1 are cytokines that stimulate tissue invasion and angiogenesis. These factors are considered as molecular targets for the therapy of glioblastoma. Bevacizumab, a recombinant humanized monoclonal antibody developed against VEGF, inhibits endothelial cell proliferation and vessel formation. Flavonoids obtained from Dimorphandra mollis and Croton betulaster have been described as proliferation inhibitors of a human glioblastoma derived cell line. VEGF and TGF-β1 levels were dosed by ELISA in a GL-15 cell line treated with bevacizumab and also with the flavonoids rutin, 5-hydroxy-7,4'-dimethoxyflavone, casticin, apigenin and penduletin. Rutin reduced the VEGF and TGF-β1 levels after 24 h but not after 72 h. The other flavonoids significantly reduced TGF-β1 production. Bevacizumab reduced only the VEGF levels in the supernatant from GL-15 cultures. These results suggest that the flavonoids studied, and commonly used in popular medicine, present an interesting subject of study due to their potential effect as angiogenic factor inhibitors.
authors.affiliation: Laboratory of Neurochemistry, Health Sciences Institute, Federal University of Bahia, Brazil.
authors.forename: Sandra
authors.initials: S
authors.lastname: Freitas
authors.forename: Silvia
authors.initials: S
authors.lastname: Costa
authors.forename: Camila
authors.initials: C
authors.lastname: Azevedo
authors.forename: Gerson
authors.initials: G
authors.lastname: Carvalho
authors.forename: Songeli
authors.initials: S
authors.lastname: Freire
authors.forename: Pedro
authors.initials: P
authors.lastname: Barbosa
authors.forename: Eudes
authors.initials: E
authors.lastname: Velozo
authors.forename: Robert
authors.initials: R
authors.lastname: Schaer
authors.forename: Marcienne
authors.initials: M
authors.lastname: Tardy
authors.forename: Roberto
authors.initials: R
authors.lastname: Meyer
authors.forename: Ivana
authors.initials: I
authors.lastname: Nascimento
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D029802:Croton / Q000737:chemistry; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D007887:Fabaceae / Q000737:chemistry; D005419:Flavonoids / Q000494:pharmacology*; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D005419:Flavonoids; D010936:Plant Extracts; D000068258:Bevacizumab